may result in poor survival for DTC compared with early RAI therapy.
Other authors claimed that the timing of RAI therapy would no impact the overall survival (OS) and disease-free survival (DFS). [4] [5] [6] [7] It is noteworthy that in these studies, clinical outcome was evaluated in terms of OS and DFS. However, OS is not sufficient or appropriate to evaluate the clinical outcome for all patients with DTC, especially for those lowto intermediate-risk patients, who had an excellent 5-year OS more than 95%. 8 Recently, a new therapy response system was proposed by the American Thyroid Association guideline (version 2015) ( Table 1) . 9 Multiple factors including clinical, biochemical, imaging (structural and functional) and cytopathology findings were taken into comprehensive consideration in this response system to assess the individual response to therapy during follow-up. It has been accepted and verified as a more objective ongoing therapy response evaluation system to reflect the clinical outcome. 10 Therefore, herein we aim to use this response system to retrospectively investigate whether the initiating time of RAI therapy would affect the clinical outcome in Chinese patients with DTC.
| MATERIALS AND METHODS
The study protocol was approved by the ethical board of the Chinese
Academy of Medical Sciences and Peking Union Medical College
Hospital. Informed consent was obtained from all individual participants included in the study.
| Patients
We Finally, 235 eligible DTC patients were enrolled in this study. 
| Clinical data

| Laboratory studies
Serum TSH was determined by chemiluminescence immunoassay (provided by Siemens Healthcare Diagnostics Inc., Tarrytown, NY), with a measuring range of 0.004-150 μIU/mL. Serum Tg and TgAb levels were determined by electrochemiluminescence immunoassay (provided by Roche Diagnostics GmbH, Mannheim, Germany). The measurement ranges of Tg and TgAb were 0.04-500 ng/mL and 10-4000 IU/mL, respectively.
| Statistical analysis
A chi-squared test was used to compare the difference in gender between the 2 groups. The Mann-Whitney U test was used to analyse 
| Patients' characteristics
Of all 235 eligible patients, the median age at diagnosis was 42
(33-50) years. The median follow-up time was 780 (440-1159)
days. Clinical and pathologic characteristics of group 1 (n = 187) and 2 (n = 48) were summarized in T A B L E 2 Clinical and pathologic characteristics
| Comparison of response to initial RAI therapy between 2 groups
The proportions of ER, IDR, BIR and SIR were significantly different between the 2 groups (P = .010; Table 3 ). Group 2 had a significantly higher IR rate (18.8% vs 4.3%, P = .001) and lower ER proportion (62.5% vs 78.1%, P = .027) than Group 1 (Table 3 ).
| Association between potential risk factors and Incomplete response to therapy
In the univariate analysis, status of T and N, stimulated Tg and interval (<3 months or ≥3 months) were significant risk factors for incomplete response (BIR + SIR) (all P < .05) (Figure 1 ), while there was no significant difference in age, gender, histological type and TSH (all P > .05).
To further explore the predictive value of interval, other interval thresholds (<1 month/≥1 month and <2 months/≥2 months) were analysed. Log-rank analysis showed that the time interval (≥3 months) was a significant risk factor for IR (P = .009), while neither threshold at 1 month nor 2 months presented prognostic value (all P > .05; Figure 1 ). According to the univariate analysis, 4 significant variables including T stage, N stage, stimulated Tg and interval (<3 months or ≥3 months) were further selected into a Cox regression multivariate analysis model, only interval was manifested to be an independent risk factor for IR (HR:3.771, 95%CI: 1.407-10.107, P = .008), N1b presented to be a borderline significant risk factor for IR (P = .053), and other factors did not present prognostic value. DTC. DTC had a 5-year mortality rate of only 2%-3%, which is most commonly caused by distant metastasis. 8 As recurrence was more common than disease-specific mortality in DTC, the risk of recurrence was the main concern in the management of DTC. Therefore, OS is inadequate to thoroughly evaluate the clinical outcome, as the essential information such as recurrence would be missed, especially in the low-to intermediate-risk individuals. In the response system proposed by ATA guideline (version 2015), the patients classified as ER have a very low risk of disease recurrence (1%-4%) and disease-specific death (<1%) over 5-10 years of follow-up, 9 while 20% of patients classified as BIR developing structurally disease. 9 Furthermore, the disease-specific death rates were as high as 11%-50% in SIR patients. 9 Therefore, the response system has been considered able to predict major clinical outcomes including recurrence and mortality. Thus, this response system has been used by us as the evaluation criteria for the clinical outcome by us in low-to intermediate-risk patients with DTC.
| DISCUSSION
Different thresholds of delay time include 3 and 6 months which have been used in various studies, according to conventional treatment practices in different countries. [3] [4] [5] [6] Given that few patients (13/235) in our study received RAI therapy more than 6 months after initial total thyroidectomy, the interval of 3 months was selected as criterion to define the early and delayed RAI therapy in this study.
Other than a study by Suman et al, 6 which claimed that delayed RAI had no impact on overall survival, we have focused on the 
4.3%) was observed in the delayed-RAI-therapy group (≥3 months).
Therefore, longer interval might be a possible cause for higher incomplete response rate in delayed-RAI-therapy patients. Further univariate and multivariate analyses confirmed the interval (≥3 months) to be an independent risk factor for incomplete response. The risk of incomplete response in patients treated by RAI delayed more than 3 months was 3.771 times higher than those who underwent RAI therapy within 3 months. Kaplan-Meier curve also showed a similar result (Figure 1) . A possible explanation for this may be the latent progression of microlesions during the prolonged interval, which was the possible mechanism in distant metastatic DTC as Higashi's study hypothesized. 3 With the above-mentioned mechanism and the results herein, which suggested that patients who received RAI therapy within 3 months achieved better response than those that were delayed, we propose that, though with no life-threatening risks, the non-high-risk DTC patients may still benefit from a timely RAI treatment and ensure them reach a disease-free status as soon as possible. Our findings also indicate that the survival analysis might be an inadequate-evaluating system which might miss the possible recurrence or unfavourable response in lowto intermediate-risk DTC cohort, which may explain the discordance between our results and those of Suman et al 6 to some extent.
In addition, we also evaluated the influence of shorter interval thresholds at 1 and 2 months, but no significant differences were found. Nonetheless, limited by the sample size and retrospective nature of our study, this analysis result of shorter intervals should be regarded with caution. 601 for T1 vs T2, P = .014 for T1 vs T3, P = .519 for T2 vs T3, (B) P = .539 for N0 vs N1a, P = .048 for N0 vs N1b, P = .023 for N1a vs N1b, (C) P = .117 for Tg < 1 ng/mL vs 1-10 ng/mL, P = .324 for Tg < 1 ng/mL vs Tg ≥ 10 ng/mL, P = .008 for Tg 1-10 ng/mL vs Tg ≥ 10 ng/mL, corrected a = 0.017 
| CONCLUSION
Our results showed that the delayed initial RAI therapy (≥3 months)
after thyroidectomy related to incomplete response in low-to intermediate-risk DTC. The non-high-risk DTC patients may benefit from a timely RAI treatment.
| Limitation
Main limitations of our study need to be noted. One is limited sample size and period of follow-up. Another is that the impact of longer intervals on response cannot be assessed as only a few patients (13/235) initiated RAI therapy more than 6 months after thyroidectomy.
